IGF::OT::IGF PREVENT EFFICACY: OPTIMIZATION OF GEM MODELS FOR HIGH-RISK COHORTS OF HUMAN PANCREATIC CYSTADENOMAS, IPMNS, AND PANINS PROGRESSION TO PDAC.
IGF::OT::IGF 预防功效:针对人类胰腺囊腺瘤、IPMNS 和 Panins 进展至 PDAC 高风险群体的 GEM 模型的优化。
基本信息
- 批准号:9152469
- 负责人:
- 金额:$ 59.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-24 至 2017-09-23
- 项目状态:已结题
- 来源:
- 关键词:AdultApoptosisBiological MarkersBreedingCancerousCell ProliferationChemopreventionChemopreventive AgentClinical TrialsContractsCystadenomaDataDevelopmentEmbryonic DevelopmentEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorGefitinibGenetic CrossesGenetically Engineered MouseHistologicHousingHumanIncidenceLesionMalignant neoplasm of pancreasModelingMolecularMouse StrainsMutateMutationPancreasPancreatic CystadenomaPancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPancreatitisPatientsPremalignantRisk FactorsSerumSignal TransductionTransgenic MiceTranslatingWritingcohortcytokinehigh riskinhibitor/antagonistmouse modelneoplasticneoplastic cellpancreatic neoplasmpre-clinicalpreventreceptortumortumor growth
项目摘要
Several Genetically Engineered Mouse (GEM) models are available which mimic some or all of the features for pancreatic ductal adenocarcinoma (PDAC) development. However, due to varied molecular features in different models, selecting the appropriate model is challenging and critical information on incidence rates, tumor multiplicity, and rate of progression for chemoprevention studies is needed. In humans, pancreatic precursor lesion development and progression occurs in the adult pancreas whereas a number of GEM models involve activation of mutated driver mutations during late embryonic development. Induction of precancerous and cancerous pancreatic lesions in these models usually occurs in the absence of pancreatitis. However, pancreatitis appears to be an important risk factor for PDAC in human patients. Hence, optimizing mouse models that represent high-risk cohorts of pancreatic cancer subjects who will participate in human chemoprevention trials will be important for translating preclinical chemopreventive observations to human clinical trials. The overall objective of this task order is to determine and characterize the temporal development of neoplastic pancreatic lesions in the genetically engineered mouse (GEM) Pdx1Cre/LSL-KrasG12D;Tif1γflox/flox model for IPMN formation and Ela-CreERT;CAG-lox-KrasG12v model for cystadenomas, pancreatitis and PanIN formation and their progression to pancreatic ductal adenocarcinoma (PDAC). These models will be optimized for use in preclinical chemoprevention studies.
有几种基因工程的小鼠(GEM)模型可模拟胰腺导管腺癌(PDAC)发育的某些或全部特征。但是,由于不同模型中的分子特征的各种特征,选择适当的模型是挑战的,并且需要有关发病率,肿瘤多样性和化学预防研究进展速率的关键信息。在人类中,胰腺前体病变的发育和进展发生在成年胰腺中,而许多宝石模型涉及在胚胎晚期发育过程中激活突变的驱动突变。在这些模型中,在没有胰腺炎的情况下,在这些模型中诱导预科剂和可取消的胰腺病变。但是,胰腺炎似乎是人类患者PDAC的重要危险因素。因此,优化代表将参与人类化学预防试验的胰腺癌受试者的高危人群的小鼠模型对于将临床前化学预防观察转换为人类临床试验非常重要。该任务顺序的总体目标是确定和表征遗传工程鼠标(GEM)PDX1CRE/LSL-KRASG12D;TIF1γFlox/Flox模型IPMN形成的肿瘤胰腺病变(GEM)PDX1CRE/LSL-KRASG12D;tif1γflox/flox模型;进展到胰腺导管腺癌(PDAC)。这些模型将被优化用于临床前化学预防研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHINTHALAPALLY RAO其他文献
CHINTHALAPALLY RAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHINTHALAPALLY RAO', 18)}}的其他基金
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
基本标题:预防临床前药物开发计划:临床前功效和中间终点生物标志物任务顺序标题:TPST-1495 在 PIRC 大鼠模型中预防结直肠癌 (CRC)
- 批准号:
10927554 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT
任务单标题:使用踪迹诱导剂预防肺腺癌 (LUAD),ONC201BASE 合同标题:预防临床前药物开发
- 批准号:
10705393 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING
基本标题:预防临床前药物开发计划:临床前疗效和中间生物标志物订单标题:预防 FAP-CRC 使用
- 批准号:
10652736 - 财政年份:2022
- 资助金额:
$ 59.94万 - 项目类别:
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
预防癌症临床前药物开发计划 - 预防三阴性乳腺癌的新型多抗原疫苗 (TNBCVAX)
- 批准号:
10503245 - 财政年份:2021
- 资助金额:
$ 59.94万 - 项目类别:
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
预防癌症临床前药物开发计划 - 预防三阴性乳腺癌的新型多抗原疫苗 (TNBCVAX)
- 批准号:
10678625 - 财政年份:2021
- 资助金额:
$ 59.94万 - 项目类别:
PREVENT EFFICACY POOL: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
预防功效池:预防癌症临床前药物开发计划
- 批准号:
10411703 - 财政年份:2021
- 资助金额:
$ 59.94万 - 项目类别:
TASK ORDER TITLE: PREVENTING COLORECTAL CANCER USING TRAIL-INDUCING ONC201 ALONE OR IN COMBINATION WITH NSAID
任务单标题:单独使用 TRAIL 诱导 ONC201 或与 NSAID 联合使用预防结直肠癌
- 批准号:
10269144 - 财政年份:2020
- 资助金额:
$ 59.94万 - 项目类别:
CHEMOPREVENTION WITH AEROSOLIZED LET-7 MICRORNA IN MOUSE MODELS OF NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA)
在非小细胞肺癌(腺癌和鳞状细胞癌)小鼠模型中使用雾化的 Let-7 微小RNA进行化学预防
- 批准号:
10020543 - 财政年份:2019
- 资助金额:
$ 59.94万 - 项目类别:
IGF::OT::IGF PROSTATE CANCER PREVENTION BY ASPIRIN AND/OR OTHER NSAIDS TORFP 2016-E03HHSN2612015000381PERIOD OF PERFORMANCE: 07/07/2016 - 03/06/2019
通过阿司匹林和/或其他非甾体抗炎药预防 IGF::OT::IGF 前列腺癌 TORFP 2016-E03HHSN2612015000381执行周期:07/07/2016 - 03/06/2019
- 批准号:
9360885 - 财政年份:2016
- 资助金额:
$ 59.94万 - 项目类别:
相似国自然基金
基于巨噬细胞表型转变探讨BTSA1诱导衰老肌成纤维细胞凋亡及促肺纤维化消退的机制
- 批准号:82370077
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
STAB1调控Fas/FasL介导牦牛胎盘滋养层细胞凋亡及胎盘炎症性流产的作用与机制研究
- 批准号:32360836
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
ATAD3A琥珀酰化调控mtDNA损伤-泛凋亡反应轴在心梗后心衰中的作用研究
- 批准号:82300434
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
胸腺肽α-1介导凋亡小体RNA改善DC功能增强TNBC化疗后抗肿瘤免疫应答的机制研究
- 批准号:82303959
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
LSD1通过使组蛋白H3K4位点去甲基化促进自噬参与肾小管上皮细胞凋亡和肾脏纤维化的机制研究
- 批准号:82300769
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of Creatine Metabolism in Necrotizing Enterocolitis
肌酸代谢在坏死性小肠结肠炎中的作用
- 批准号:
10724729 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
Biomarker of Pancreatic B-cell Loss Predicting Progression to Type 2 Diabetes After Gestational Diabetes
胰腺 B 细胞损失的生物标志物可预测妊娠期糖尿病后进展为 2 型糖尿病
- 批准号:
10583645 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
Determinants of cardioprotection by circulating prohibitin-1 during sepsis
败血症期间循环抑制素 1 的心脏保护作用的决定因素
- 批准号:
10577340 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
Mapping Integrated Single-Cell Chromatin Accessibility with the Single-Cell Transcriptional Landscape in Pediatric Type 2 Diabetes
绘制儿科 2 型糖尿病中单细胞染色质可及性与单细胞转录景观的整合图谱
- 批准号:
10664557 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别:
Effect of Acetylcholinesterase inhibitors on Bone Metabolism and Fracture Risk Factors among older adults with mild to moderate Alzheimer's Disease
乙酰胆碱酯酶抑制剂对患有轻至中度阿尔茨海默病的老年人骨代谢和骨折危险因素的影响
- 批准号:
10739853 - 财政年份:2023
- 资助金额:
$ 59.94万 - 项目类别: